MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202517084288 A) filed by Merck Sharp & Dohme Llc, Rahway, U.S.A., on Sept. 4, for 'alpha-synuclein binders and methods of use.'
Inventor(s) include Bennacef, Idriss; Fawaz, Maria V.; Hostetler, Eric D; Mitchell, Helen; Roecker, Anthony J.; Shaw, Anthony W.; Stump, Craig A.; and Tong, Ling.
The application for the patent was published on Sept. 26, under issue no. 39/2025.
According to the abstract released by the Intellectual Property India: "The invention is directed to compounds of Formula I (I) or their pharmaceutically acceptable salts, which may be suitable for imaging alpha-synuclein pathology and hence are useful in binding and imaging alpha-synuclein aggregates in patients with Parkinson's Disease. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study alpha-synuclein in brain in vivo to allow diagnosis of Parkinson's Disease and other neurodegenerative diseases characterized by alpha-synuclein pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Parkinson's Disease and other neurodegenerative diseases characterized by alpha-synuclein pathology."
The patent application was internationally filed on Feb. 29, 2024, under International application No.PCT/US2024/017922.
Disclaimer: Curated by HT Syndication.
